Instil Bio, Inc. (TIL)

NASDAQ: TIL · IEX Real-Time Price · USD
0.587
+0.005 (0.82%)
Jun 5, 2023, 1:00 PM EDT - Market open
0.82%
Market Cap 75.85M
Revenue (ttm) n/a
Net Income (ttm) -226.13M
Shares Out 130.08M
EPS (ttm) -1.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 159,427
Open 0.582
Previous Close 0.582
Day's Range 0.570 - 0.598
52-Week Range 0.471 - 7.710
Beta 1.28
Analysts Buy
Price Target 9.50 (+1,518.12%)
Earnings Date May 11, 2023

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 192
Stock Exchange NASDAQ
Ticker Symbol TIL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 1,518.12% from the latest price.

Price Target
$9.5
(1,518.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 ...

3 weeks ago - GlobeNewsWire

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Instil confirms cash runway beyond 2026

2 months ago - GlobeNewsWire

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Company anticipates cash resources to provide runway beyond 2026

4 months ago - GlobeNewsWire
}

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

4 months ago - Barrons

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause

5 months ago - GlobeNewsWire

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The i...

6 months ago - Business Wire

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

DALLAS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing next-generation tumor infiltratin...

6 months ago - GlobeNewsWire

Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - November 21, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in ...

7 months ago - Newsfile Corp
}

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23

7 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to cont...

7 months ago - PRNewsWire

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...

7 months ago - Newsfile Corp

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...

7 months ago - GlobeNewsWire

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...

7 months ago - Newsfile Corp
}

Instil Bio Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - November 3, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in t...

7 months ago - Newsfile Corp

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...

7 months ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...

7 months ago - Newsfile Corp

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Instil Bio, Inc. ...

7 months ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R.

7 months ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TIL #TIL--The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

7 months ago - Business Wire

EQUITY ALERT: Rosen Law Firm Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation – TIL

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Instil Bio, Inc. (NASDAQ: TIL)...

7 months ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TIL #TIL--The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

7 months ago - Business Wire

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials

Shares of Instil Bio Inc. TIL, +14.38% tumbled 35.1% in premarket trading on Monday after the company said it paused enrollment in clinical trials for two experimental cell therapies due to manufactur...

7 months ago - Market Watch

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

DALLAS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...

7 months ago - GlobeNewsWire